東陽光藥(01558.HK)公佈年度業績：淨虧損約5.88億元，可威銷售額同比跌逾七成
格隆匯3月21日丨東陽光藥(01558.HK)公佈，截至2021年12月31日止年度，公司營業額為人民幣9.14億元，同比減少61.08%；歸屬於公司權益持有人的虧損及全面虧損總額(不考慮可轉換債券影響)為人民幣4.15億元，去年同期的歸屬於公司權益持有人的溢利及全面收益總額(不考慮可轉換債券影響)人民幣5.90億元；歸屬於公司權益持有人的虧損及全面虧損總額(考慮可轉換債券影響)為人民幣5.88億元，去年同期的歸屬於公司權益持有人的溢利及全面收益總額(考慮可轉換債券影響)人民幣8.39億元，每股基本虧損為人民幣0.67元。
2021年，集團營業額為人民幣9.14億元，較2020年減少61.08%，原因主要是由於新型冠狀病毒疫情爆發初期，中國國內人口流動性降低，醫院的診療活動數量、處方量及藥品銷量也隨之下降，集團核心產品可威為主要用於等級醫院銷售的處方藥，其銷售量亦受新型冠狀病毒疫情影響而下降。報吿期內，集團的阿立哌唑片、阿立哌唑口崩片、恩他卡朋片、草酸艾司西酞普蘭片、非布司他片、阿託伐他汀鈣片、阿哌沙班片、利伐沙班片、枸櫞酸西地那非片、琥珀酸美託洛爾緩釋片等多個仿製藥產品獲批准上市，生物製劑產品甘精胰島素注射液獲批准上市，以上產品的獲批准上市有利於集團積極開拓新的市場領域，使集團的產品組合持續優化，更有利於集團未來業績的提升。截至2021年12月31日，集團已有13個產品中標全國藥品帶量採購。藉助帶量採購相關產品，除了豐富集團收入結構，增加集團盈利外，集團亦可進一步拓展相關產品科室渠道，提升本集團品牌影響力，為未來新產品上市奠定市場基礎。
具體業績方面，報吿期內，集團核心產品可威的銷售額為人民幣5.55億元，較2020年同期減少73.19%。歸屬於公司權益持有人的虧損及全面虧損總額(考慮可轉換債券影響)為人民幣5.88億元。截至公吿日期，集團從廣東東陽光藥業收購之仿製藥有28個產品已獲中國國家藥品監督管理局審批完畢並獲准上市。隨着仿製藥產品的陸續獲批上市，在進一步豐富集團的產品組合的同時，也為廣大患者提供質價雙優的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
